WEST PHARMACEUTICAL SERVICES (WST:NYSE)
$337.67 6.42 (1.9381%)
Analysed WEST PHARMACEUTICAL SERVICES (WST:NYSE) News Sources
WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook
24-07-2026
yahoo.com
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
24-07-2026
yahoo.com
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs
24-07-2026
yahoo.com
Here's Why You Should Add Cencora Stock to Your Portfolio Now
24-07-2026
yahoo.com
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
24-07-2026
yahoo.com
West Pharmaceutical (WST) Signs Decade Long Daikyo Distribution Deal Beyond Japan
26-07-2026
yahoo.com
Beat the Market Like Zacks: Monster Beverage, Carpenter Tech, Usio in Focus
27-07-2026
yahoo.com
Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings
27-07-2026
yahoo.com
MMED Gets Medicare Coverage for Flex and Broadens Diabetes Care Access
27-07-2026
yahoo.com
STERIS' Q1 Earnings on Deck: What's in Store for the Stock?
28-07-2026
yahoo.com
What is the current price of WEST PHARMACEUTICAL SERVICES (WST:NYSE)?
The current price of WEST PHARMACEUTICAL SERVICES (WST:NYSE) is $337.67.
WEST PHARMACEUTICAL SERVICES (WST:NYSE) absolute price change since previous trading day?
The absolute price change of WEST PHARMACEUTICAL SERVICES (WST:NYSE) since the previous trading day is $6.42.
WEST PHARMACEUTICAL SERVICES (WST:NYSE) percentage price change since previous trading day?
The percentage price change of WEST PHARMACEUTICAL SERVICES (WST:NYSE) since the previous trading day is 1.9381%.
What is the most recent average sentiment score for WEST PHARMACEUTICAL SERVICES (WST:NYSE)?
The most recent average sentiment score for WEST PHARMACEUTICAL SERVICES (WST:NYSE) is 70 out of 100.
What is the most recent average sentiment for WEST PHARMACEUTICAL SERVICES (WST:NYSE)?
The most recent sentiment for WEST PHARMACEUTICAL SERVICES (WST:NYSE) is .
SEC-8K** Filing Available For WEST PHARMACEUTICAL SERVICES (WST:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.